Analyzing Illumina (ILMN) & EDAP TMS (EDAP)
Illumina (NASDAQ: ILMN) and EDAP TMS (NASDAQ:EDAP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Valuation & Earnings
This table compares Illumina and EDAP TMS’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Illumina||$2.49 billion||12.06||$666.78 million||$5.10||40.32|
|EDAP TMS||$44.00 million||2.07||$270,377.00||($0.01)||-313.69|
Illumina has higher revenue and earnings than EDAP TMS. EDAP TMS is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
This table compares Illumina and EDAP TMS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations for Illumina and EDAP TMS, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Illumina currently has a consensus target price of $188.88, indicating a potential downside of 8.14%. EDAP TMS has a consensus target price of $6.50, indicating a potential upside of 107.01%. Given EDAP TMS’s stronger consensus rating and higher possible upside, analysts plainly believe EDAP TMS is more favorable than Illumina.
Insider & Institutional Ownership
93.3% of Illumina shares are held by institutional investors. Comparatively, 9.4% of EDAP TMS shares are held by institutional investors. 1.6% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Illumina has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, EDAP TMS has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
Illumina beats EDAP TMS on 10 of the 13 factors compared between the two stocks.
Illumina Company Profile
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
EDAP TMS Company Profile
EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.